SeaStar Medical and AREVA Institute Collaborate on Innovative Burn Treatment Research with DoD Grant
A $2 million DoD grant supports SeaStar Medical and AREVA Institute's research into SCD therapy for reducing hyperinflammation in severe burns, potentially revolutionizing treatment for military and civilian patients.
Severe burns, inhalation injuries, and septicemia often lead to destructive hyperinflammation, posing significant risks such as organ failure and death. The Autonomous Reanimation and Evacuation (AREVA) Research Institute, in collaboration with SeaStar Medical, has been awarded a grant by the United States Department of Defense (DoD) to explore innovative treatments for these conditions. The grant, part of the 2024 Military Burn Research Program, will fund a three-year study starting in July 2025, focusing on SeaStar Medical's Selective Cytopheretic Device (SCD) therapy.
The SCD therapy aims to neutralize destructive hyperinflammation by treating blood outside the body, offering a novel approach to improve survival rates among critically wounded service members and civilian patients. This therapy, used alongside continuous renal replacement therapy (CRRT), is designed to support organ recovery, potentially reducing the need for lifelong dialysis. Dr. Andriy Batchinsky, principal investigator at AREVA, highlights the potential impact of this research on patients with infection- and trauma-related organ failures.
SeaStar Medical's SCD therapy has already shown promise in treating pediatric acute kidney injury, with clinical trials demonstrating reduced mortality rates and dialysis duration. The current study aims to expand the therapy's applications, including adult acute kidney injury, with the potential to address a wide range of acute and chronic diseases. The collaboration between SeaStar Medical and AREVA Institute, supported by The Geneva Foundation, represents a significant advancement in the treatment of severe burns and related conditions, offering hope for improved patient outcomes.